Literature DB >> 9234948

Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six.

A P Durbin1, J W Siew, B R Murphy, P L Collins.   

Abstract

A reconstituted transcription and RNA replication system for human parainfluenza virus type 3 (HPIV3) was developed using components expressed intracellularly from transfected plasmids driven by T7 RNA polymerase supplied by a vaccinia virus recombinant. The system is based on a negative-sense analog of HPIV3 genomic RNA in which the viral genes were deleted and replaced with that encoding bacterial chloramphenicol acetyl transferase (CAT). The N, P, and L proteins expressed from cotransfected plasmids were necessary and sufficient to direct efficient transcription and RNA replication. Transcription yielded subgenomic polyadenylated mRNA, which was isolated by oligo(dT) chromatography. RNA replication yielded a mini-antigenome and progeny minigenome, which were shown to be encapsidated based on resistance to digestion with micrococcal nuclease. A panel of cDNAs was constructed to encode minigenomes which differed in length by single-nucleotide increments. Transcription and RNA replication in the reconstituted system were most efficient for the minigenome whose length was an even multiple of six. Both RNA replication and transcription appeared to be governed by the rule. However, minigenomes whose lengths were one nucleotide greater than or less than an even multiple of six also were very active, especially in RNA replication, indicating that the rule was not absolute.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234948     DOI: 10.1006/viro.1997.8633

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  33 in total

1.  "Rule of six": how does the Sendai virus RNA polymerase keep count?

Authors:  D Vulliémoz; L Roux
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Human parainfluenza virus type 3 (HPIV-3): construction and rescue of an infectious, recombinant virus expressing the enhanced green fluorescent protein (EGFP).

Authors:  Jason P Roth; Joseph K-K Li; Dale L Barnard
Journal:  Curr Protoc Microbiol       Date:  2010-05

3.  A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.

Authors:  J E Bailly; J M McAuliffe; A P Durbin; W R Elkins; P L Collins; B R Murphy
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium.

Authors:  Liqun Zhang; Alexander Bukreyev; Catherine I Thompson; Brandy Watson; Mark E Peeples; Peter L Collins; Raymond J Pickles
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Analysis of nucleotides 13-96 of the human parainfluenza virus type 3 antigenomic promoter reveals positive- and negative-acting replication elements.

Authors:  Jill R Gander; LeeAnne M Schwan; Michael A Hoffman
Journal:  Virology       Date:  2011-08-30       Impact factor: 3.616

6.  Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes.

Authors:  E Mühlberger; B Lötfering; H D Klenk; S Becker
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

7.  Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.

Authors:  M H Skiadopoulos; A P Durbin; J M Tatem; S L Wu; M Paschalis; T Tao; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.

Authors:  T Tao; A P Durbin; S S Whitehead; F Davoodi; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

Review 9.  Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited.

Authors:  D Kolakofsky; T Pelet; D Garcin; S Hausmann; J Curran; L Roux
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

10.  A recombinant, infectious human parainfluenza virus type 3 expressing the enhanced green fluorescent protein for use in high-throughput antiviral assays.

Authors:  Jason P Roth; Joseph K-K Li; Donald F Smee; John D Morrey; Dale L Barnard
Journal:  Antiviral Res       Date:  2009-02-02       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.